Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
31.80
-0.33 (-1.03%)
Aug 18, 2026, 11:41 AM EDT - Market open
Stoke Therapeutics Employees
Stoke Therapeutics had 170 employees as of December 31, 2025. The number of employees increased by 42 or 32.81% compared to the previous year.
Employees
170
Change (1Y)
42
Growth (1Y)
32.81%
Revenue / Employee
$162,282
Profits / Employee
-$1,222,959
Market Cap
2.05B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 170 | 42 | 32.81% |
| Dec 31, 2024 | 128 | 18 | 16.36% |
| Dec 31, 2023 | 110 | -7 | -5.98% |
| Dec 31, 2022 | 117 | 15 | 14.71% |
| Dec 31, 2021 | 102 | 23 | 29.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Agios Pharmaceuticals | 540 |
| Zenas BioPharma | 167 |
| Aurinia Pharmaceuticals | 128 |
| Septerna | 123 |
| Taysha Gene Therapies | 99 |
| Mesoblast | 81 |
| GH Research | 73 |
STOK News
- 6 days ago - Stoke Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 13 days ago - Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 14 days ago - Stoke Therapeutics price target lowered to $58 from $60 at Canaccord - TheFly
- 14 days ago - Stoke Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - Stoke Therapeutics Earnings release: Q2 2026 - Filings
- 14 days ago - Stoke Therapeutics Quarterly report: Q2 2026 - Filings
- 14 days ago - Stoke Therapeutics Slides: Q2 2026 - Filings
- 14 days ago - Stoke Therapeutics reports Q2 EPS (93c), consensus (78c) - TheFly